Intensive Post-remission Therapy Does Not Decrease Relapse After Allotransplants for Acute Myeloid Leukaemia in 1st Remission and Should Not Be Given

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2025 Mar 13

PMID 40074851

Authors

E Rodriguez-Arboli

G L Phillips

T S Pardee

H M Lazarus

R P Gale

Affiliations

Soon will be listed here.

References

Weigert N, Rowe J, Lazarus H, Yisraeli Salman M . Consolidation in AML: Abundant opinion and much unknown. Blood Rev. 2021; 51:100873. DOI: 10.1016/j.blre.2021.100873. View

Cahn J, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A . No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000; 110(2):308-14. DOI: 10.1046/j.1365-2141.2000.02178.x. View

Tallman M, Rowlings P, Milone G, Zhang M, Perez W, Weisdorf D . Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000; 96(4):1254-8. View

Warlick E, Paulson K, Brazauskas R, Zhong X, Miller A, Camitta B . Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013; 20(2):202-8. PMC: 3924751. DOI: 10.1016/j.bbmt.2013.10.023. View

Yeshurun M, Labopin M, Blaise D, Cornelissen J, Sengeloev H, Vindelov L . Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working.... Cancer. 2013; 120(6):855-63. DOI: 10.1002/cncr.28498. View

Rashidi A, Linden M, DeFor T, Warlick E, Bejanyan N, Yohe S . History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2017; 92(10):1032-1036. PMC: 5734672. DOI: 10.1002/ajh.24834. View

How J, Vij K, Ebadi M, DeFor T, Romee R, Dolan M . Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2018; 93(12):E381-E383. PMC: 6239215. DOI: 10.1002/ajh.25262. View

Yeshurun M, Wolach O . When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?. Curr Opin Hematol. 2017; 25(2):75-80. DOI: 10.1097/MOH.0000000000000410. View

Zhu Y, Gao Q, Du J, Hu J, Liu X, Zhang F . Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis. Ann Hematol. 2018; 97(9):1519-1526. DOI: 10.1007/s00277-018-3414-6. View

10.

Liu J, Wu D, Liu Q, Chang Y, Xu Y, Huang F . More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J (Engl). 2023; 136(15):1855-1863. PMC: 10406017. DOI: 10.1097/CM9.0000000000002347. View

11.

Hourigan C, Gale R, Gormley N, Ossenkoppele G, Walter R . Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017; 31(7):1482-1490. DOI: 10.1038/leu.2017.113. View

12.

Venditti A, Gale R, Buccisano F, Ossenkoppele G . Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?. Leukemia. 2020; 34(4):963-965. DOI: 10.1038/s41375-020-0780-6. View

13.

Paras G, Morsink L, Othus M, Milano F, Sandmaier B, Zarling L . Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022; 139(11):1694-1706. PMC: 8931514. DOI: 10.1182/blood.2021014804. View

14.

Rodriguez-Arboli E, Othus M, Orvain C, Zarling L, Sandmaier B, Milano F . Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2022; 108(1):273-277. PMC: 9827162. DOI: 10.3324/haematol.2022.281631. View

15.

Orvain C, Rodriguez-Arboli E, Othus M, Sandmaier B, Deeg H, Appelbaum F . Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. Cancers (Basel). 2023; 15(2). PMC: 9856876. DOI: 10.3390/cancers15020352. View

16.

Rodriguez-Arboli E, Othus M, Freeman S, Buccisano F, Ngai L, Thomas I . Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML). Leukemia. 2024; 38(10):2266-2269. PMC: 11438566. DOI: 10.1038/s41375-024-02378-5. View

17.

Cao Y, Huo W, Huang J, Yang Y, Wang Y, Chang Y . MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J. 2024; 14(1):8. PMC: 10791633. DOI: 10.1038/s41408-024-00976-1. View

18.

Buckley S, Wood B, Othus M, Hourigan C, Ustun C, Linden M . Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017; 102(5):865-873. PMC: 5477605. DOI: 10.3324/haematol.2016.159343. View

19.

Zheng C, Dai R, Gale R, Zhang M . Causal inference in randomized clinical trials. Bone Marrow Transplant. 2019; 55(1):4-8. DOI: 10.1038/s41409-018-0424-x. View

20.

Othus M, Gale R, Hourigan C, Walter R . Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2019; 55(5):843-850. PMC: 7462748. DOI: 10.1038/s41409-019-0729-4. View